Literature DB >> 11929823

Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.

Hui Huang1, Fang Li, John R Gordon, Jim Xiang.   

Abstract

The lack of efficient T-cell infiltration of tumors is a major obstacle to successful adoptive T-cell therapy. We have shown that transplanted SP2/0 myeloma tumors that have been engineered to express lymphotactin (Lptn) invariably regress under the influence of infiltrating XCR1+T cells and neutrophils. Herein, we characterize these T cells and investigate their therapeutic efficacy, either alone or with Lptn gene therapy. After stimulation with SP2/0 cells, these T cells were CD25+FasL+L-selectin-, expressed XCR-1, and were chemoattracted by Lptn in vitro. They comprised 66% CD4+ Th1 and 33% CD8+ Tc1 cells, both of which expressed significant amounts of IFN-gamma, perforin, and tumor necrosis factor-alpha, but not interleukin-4. The CD4+ Th1 and CD8+ Tc1 cells, which were inhibited and stimulated, respectively, for proliferation with Lptn signaling, displayed 38 and 84% specific killing, respectively, for Ia(d)/H-2K(d)-expressing SP2/0 tumor cells (E:T ratio, 100). In vivo, combined intratumoral Lptn gene transfer and adoptive immunotherapy with these CD4+ and CD8+ T cells eradicated well-established SP2/0 tumors in six of eight mice, and dramatically slowed tumor growth in the other two mice. Cell tracking using labeled T cells confirmed that these cells infiltrated better into the Lptn-expressing tumors than non-Lptn-expressing ones. Control or Lptn adenoviral treatments by themselves did not alter the lethal outcome for tumor-bearing mice, nor did T-cell therapy by itself, although the latter two treatments did slow its time frame. Combined Lptn gene transfer and adoptive CD4+ or CD8+ cell transfers were not nearly as efficacious as the combined Lptn gene and unfractionated T-cell transfers. Taken together, our data provide solid evidence of a potent synergy between adoptive CD4+ and CD8+ T-cell therapy and Lptn gene transfer into tumor tissues, which culminated in the eradication of well-established tumor masses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929823

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

Review 1.  Adoptive immunotherapy for cancer: building on success.

Authors:  Luca Gattinoni; Daniel J Powell; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

2.  CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes.

Authors:  Hui Huang; Siguo Hao; Fang Li; Zhenmin Ye; Junbao Yang; Jim Xiang
Journal:  Immunology       Date:  2007-02       Impact factor: 7.397

3.  Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes.

Authors:  Zheng Zhang; Qi He; Ying Tao; Juan Guo; Feng Xu; Ling-Yun Wu; You-Shan Zhao; Dong Wu; Li-Yu Zhou; Ji-Ying Su; Lu-Xi Song; Chao Xiao; Xiao Li; Chun-Kang Chang
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

4.  Transfection of colorectal cancer cells with chemokine MCP-3 (monocyte chemotactic protein-3) gene retards tumor growth and inhibits tumor metastasis.

Authors:  Jin-Yue Hu; Guan-Cheng Li; Wen-Meng Wang; Jian-Gao Zhu; Yue-Fei Li; Guo-Hua Zhou; Qu-Bing Sun
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

5.  In-vitro activation of cytotoxic T lymphocytes by fusion of mouse hepatocellular carcinoma cells and lymphotactin gene-modified dendritic cells.

Authors:  Xi-Ling Sheng; Hao Zhang
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

6.  Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.

Authors:  Deepa Kolaseri Krishnadas; Lei Bao; Fanqi Bai; Satheesh Cheeyancheri Chencheri; Kenneth Lucas
Journal:  Tumour Biol       Date:  2014-03-02

7.  Programmed cell death 2 functions as a tumor suppressor in osteosarcoma.

Authors:  Yuanxun Yang; Yan Jin; Wenxi Du
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells.

Authors:  Zuqiang Liu; Hae S Noh; Janet Chen; Jin H Kim; Louis D Falo; Zhaoyang You
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

9.  Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses.

Authors:  Takekazu Iuchi; Seagal Teitz-Tennenbaum; Jianhua Huang; Bruce G Redman; Steven D Hughes; Mu Li; Guihua Jiang; Alfred E Chang; Qiao Li
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

10.  XCL1 enhances regulatory activities of CD4+ CD25(high) CD127(low/-) T cells in human allergic asthma.

Authors:  Khoa D Nguyen; Alison Fohner; Jerome D Booker; Chen Dong; Alan M Krensky; Kari C Nadeau
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.